you guys need to wind down the wishful thinking. To get a marketing authorisation on ph2 data you need to be running a ph3. Read the latest quarterly- aipac ph3 is not a priority and neither is the MA - and rightly so. As an investor you dont want them to sink 50-100m into a ph3 that has a high chance of missing the mark or being redundant due to new drug advancements. Treatment landscape for mbc is changing rapidly so sample population from ph2 will not be the same in ph3 which means you have a high risk of ph2 data not extrapolating into ph3 (just like we say with ph1 and ph2 of aipac).
you guys need to wind down the wishful thinking. To get a...
-
- There are more pages in this discussion • 1,800 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.015(3.57%) |
Mkt cap ! $619.6M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 44.0¢ | 41.5¢ | $1.416M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 38735 | 42.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 41215 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |